GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krebs Biochemicals & Industries Ltd-$

Krebs Biochemicals & Industries Q2 FY27 Results: Net Loss of (539.85) Rs. In lacs

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 29 Oct 2026, 01:00 PM IST  ·  BSE ID: 41b7180b-c26f-4b68-aa8a-d4f5db1c705f
View Original BSE Filing (PDF)
💡
In Simple Terms
Krebs Biochemicals reported a loss of (539.85) Rs. In lacs for the latest quarter, with its main factory still shut down.
🤖 AI Summary
  • Net Loss for Q2 FY27 was (539.85) Rs. In lacs for the quarter ended September 30, 2026.
  • Revenue from Operations reached 579.03 Rs. In lacs for Q2 FY27, compared to 416.74 Rs. In lacs in Q2 FY26.
  • Half-year net loss was (788.33) Rs. In lacs for the period ended September 30, 2026.
  • Vizag manufacturing unit remains closed since February 7, 2025, due to a Pollution Control Board order.
  • The Board approved amalgamation with Ipca Laboratories Limited, with an appointed date of April 1, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
579.03 Rs. In lacs
Net Profit / (Loss) for the period (Q2 FY27)
(539.85) Rs. In lacs
Basic EPS (Q2 FY27)
(2.50) Rs. In lacs
Revenue from Operations (Half Year FY27)
1,277.38 Rs. In lacs
Net Profit / (Loss) for the period (Half Year FY27)
(788.33) Rs. In lacs
Net Cash Flow from Operating Activities (Half Year FY27)
299.78 Rs. In lacs
🏢 How This Affects the Company
📈
Business Impact
The continued closure of the Vizag manufacturing unit since February 7, 2025, restricts the company's operational capacity and revenue generation potential. Revenue from Operations for the quarter was 579.03 Rs. In lacs.
💰
Financial Impact
The company reported a net loss of (539.85) Rs. In lacs for Q2 FY27, contributing to a half-year net loss of (788.33) Rs. In lacs. Total expenses for the quarter amounted to 1122.62 Rs. In lacs.
⚙️
Operational Impact
The indefinite closure of the primary manufacturing unit directly impacts production and delivery capabilities. Management is in dialogue with the Pollution Control Board for revocation of the closure order.
⚠️
Risk Impact
The ongoing closure order from the Andhra Pradesh Pollution Control Board poses a significant regulatory and operational risk, impacting the company's ability to operate and generate profits.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported financial performance, including the net loss of (539.85) Rs. In lacs for the quarter and the ongoing manufacturing unit closure.
🔍
Management Signal
Management is actively engaging with the Pollution Control Board to revoke the closure order for the Vizag unit, signaling efforts to restore full operational capacity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Updates on the Vizag manufacturing unit closure order from the Pollution Control Board.
Progress and approvals related to the proposed amalgamation with Ipca Laboratories Limited.
Q3 FY27 financial results to assess any changes in revenue and loss trends.
HIGH RISK The company faces significant operational and financial risks due to sustained losses and the prolonged closure of its key manufacturing unit.
💡 Investor Takeaway
Krebs Biochemicals & Industries reported a Q2 FY27 net loss of (539.85) Rs. In lacs and a half-year net loss of (788.33) Rs. In lacs. Revenue from Operations for Q2 FY27 was 579.03 Rs. In lacs. The Vizag manufacturing unit remains closed as of September 30, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from Operations increased to 579.03 Rs. In lacs in Q2 FY27 from 416.74 Rs. In lacs in Q2 FY26.
  • Net Cash Flow from Operating Activities was 299.78 Rs. In lacs for the half year ended September 30, 2026, compared to (167.56) Rs. In lacs in the prior half year.

⚠️ Concerns

  • Company reported a net loss of (539.85) Rs. In lacs for Q2 FY27 and a half-year net loss of (788.33) Rs. In lacs.
  • The Vizag manufacturing unit remains closed since February 7, 2025, due to an Andhra Pradesh Pollution Control Board order.
📅 Company Track Record
Krebs Biochemicals & Industries Ltd previously reported unaudited financial results for Q1 FY27 (quarter ended June 30, 2026). The company's Vizag manufacturing unit has been closed since February 7, 2025, following an order from the Andhra Pradesh Pollution Control Board. The Board approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited on June 26, 2026, with an appointed date of April 1, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Krebs Biochemicals & Industries Ltd's net profit/loss for Q2 FY27?
Krebs Biochemicals & Industries Ltd reported a net loss of (539.85) Rs. In lacs for the quarter ended September 30, 2026 (Q2 FY27).
What was Krebs Biochemicals & Industries Ltd's revenue from operations for Q2 FY27?
Revenue from Operations for Krebs Biochemicals & Industries Ltd was 579.03 Rs. In lacs for the quarter ended September 30, 2026.
What is the status of Krebs Biochemicals & Industries Ltd's Vizag manufacturing unit?
The Vizag manufacturing unit of Krebs Biochemicals & Industries Ltd continued to remain closed as of September 30, 2026, pursuant to an order dated February 7, 2025, by the Andhra Pradesh Pollution Control Board.
What was Krebs Biochemicals & Industries Ltd's net loss for the half year ended September 30, 2026?
The net loss for Krebs Biochemicals & Industries Ltd for the half year ended September 30, 2026, was (788.33) Rs. In lacs.
Has Krebs Biochemicals & Industries Ltd announced any amalgamation?
Yes, the Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited at their meeting held on June 26, 2026, with an appointed date of April 1, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.